Imbruvica
South San Francisco
About Imbruvica
Imbruvica is an oral medicine for treating CLL, SLL, and MCL by blocking BTK protein in cancer cells.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Funding stage: Seed
- Last round: Seed (Jan 2013)
- Website: imbruvica.com
- Phone: +1 40 8215 3000
Canonical: https://fsome.com/organization/imbruvica-3763329 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.